AspenBio Advances Several High Value Late-Stage Human and Animal Bio Pharma Products, Including the First Blood-based Test for Human Appendicitis
CASTLE ROCK, Colo., Aug. 20 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (OTC Bulletin Board: APNB) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, reported results for the second quarter ended June 30, 2007.
Richard Donnelly, AspenBio's president and CEO, said, "Recent product development activities demonstrate substantial progress in the second quarter. We remain confident that 2007 will be a major inflection point for AspenBio, as we proceed towards achieving key milestones and delivering on important new products, like our breakthrough appendicitis triage blood tests, AppyScore(TM) and AppyScreen(TM)."
Mr. Donnelly further stated, "Following the 2007 second quarter completion of the conversion of warrants that increased our cash position to more than $11 million, we have accelerated development of our key products. This includes making important additions to our scientific staff, engaging well known FDA consultants, and signing high quality contract manufacturers to advance both the appendicitis blood tests and BoviPure FSH(TM) products. We continued to see positive field trial results for all of our top products."
Second Quarter 2007 Key Highlights
AppyScore & AppyScreen: Substantial progress was made in the
development of AspenBio's breakthrough products; AppyScore Appendicitis
Triage Blood Test for emergency rooms, and its sister product, AppyScreen
(being designed as a point-of-care test for physician offices). Results
from the ongoing 400- patient pre-United States Food and Drug
Administration ("FDA") trials of the AppyScore blood test continue to
demonstrate high sensitivity levels of 94% to 97% in the ability to
identify patients with appendicitis. While this pre-FDA trial has taken
longer than orig
|SOURCE AspenBio Pharma, Inc.|
Copyright©2007 PR Newswire.